Press Releases
Samsung Biologics recognized for its outstanding disclosure practices and corporate governance reporting
Samsung Biologics has been selected as a company of excellence by the Korea Exchange this year for its efforts in providing corporate disclosures.
Every year since 2019, the Korea Exchange has been selecting corporations who continue to provide excellent English disclosures, recognizing their efforts to further enhance accessibility to information with aims to ultimately fuel investments into the domestic market from foreign investors.
Since its listing in November 2016, Samsung Biologics has actively provided useful information in a timely manner, particularly to foreign investors, including occasional mandatory and self-disclosure items as part of its shareholder-friendly policy. The company has been transparent in disclosing the current status through a corporate governance report in May every year. In addition, the company continues to publish business and sales reports in on the company website.
“As a global CDMO company with the world’s largest biopharmaceutical manufacturing capacity, we continue to focus on providing useful corporate information to our clients and investors around the world. We will do our best in being a highly trusted company by demonstrating transparency and robust governance throughout our business activities,” said John Rim, CEO of Samsung Biologics.
Samsung Biologics has been selected as a company of excellence by the Korea Exchange this year for its efforts in providing corporate disclosures.
Every year since 2019, the Korea Exchange has been selecting corporations who continue to provide excellent English disclosures, recognizing their efforts to further enhance accessibility to information with aims to ultimately fuel investments into the domestic market from foreign investors.
Since its listing in November 2016, Samsung Biologics has actively provided useful information in a timely manner, particularly to foreign investors, including occasional mandatory and self-disclosure items as part of its shareholder-friendly policy. The company has been transparent in disclosing the current status through a corporate governance report in May every year. In addition, the company continues to publish business and sales reports in on the company website.
“As a global CDMO company with the world’s largest biopharmaceutical manufacturing capacity, we continue to focus on providing useful corporate information to our clients and investors around the world. We will do our best in being a highly trusted company by demonstrating transparency and robust governance throughout our business activities,” said John Rim, CEO of Samsung Biologics.